EyePoint gets third positive safety review for wet AMD drug trials

May 14, 2026 7:01 AM

EyePoint Inc. (NASDAQ: EYPT) announced that an independent Data Safety Monitoring Committee recommended continuing both Phase 3 trials of its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found